Stock Track | Adaptive Biotechnologies Soars 8.85% in Pre-market on Strong Q1 Earnings Beat and Analyst Support

Stock Track05-06 22:05

Adaptive Biotechnologies Corp's stock soared 8.85% in pre-market trading on Wednesday, following the company's better-than-expected first-quarter 2026 financial results and positive analyst reactions.

The significant price increase was driven by the company reporting quarterly revenue of $70.9 million, which exceeded analyst estimates of approximately $61 million and represented a 35% increase year-over-year. Adaptive Biotechnologies also reported a narrower quarterly loss per share of $0.13, beating the consensus estimate of a $0.17-$0.18 loss. The company raised its full-year MRD revenue guidance to $260-$270 million, reflecting accelerating adoption of its clonoSEQ test.

Further bolstering investor sentiment, multiple analysts maintained positive ratings on the stock, with J.P. Morgan reiterating a Buy rating with a $19.00 price target and Piper Sandler maintaining a Buy rating with a $20.00 price target, highlighting continued confidence in the company's growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120593580?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120593580","market":"nz","top_or_hot":-1,"title":"Stock Track | Adaptive Biotechnologies Soars 8.85% in Pre-market on Strong Q1 Earnings Beat and Analyst Support","media":"Stock Track","content":"<p>Adaptive Biotechnologies Corp's stock soared 8.85% in pre-market trading on Wednesday, following the company's better-than-expected first-quarter 2026 financial results and positive analyst reactions.</p><p>The significant price increase was driven by the company reporting quarterly revenue of $70.9 million, which exceeded analyst estimates of approximately $61 million and represented a 35% increase year-over-year. Adaptive Biotechnologies also reported a narrower quarterly loss per share of $0.13, beating the consensus estimate of a $0.17-$0.18 loss. The company raised its full-year MRD revenue guidance to $260-$270 million, reflecting accelerating adoption of its clonoSEQ test.</p><p>Further bolstering investor sentiment, multiple analysts maintained positive ratings on the stock, with J.P. Morgan reiterating a Buy rating with a $19.00 price target and Piper Sandler maintaining a Buy rating with a $20.00 price target, highlighting continued confidence in the company's growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Adaptive Biotechnologies Soars 8.85% in Pre-market on Strong Q1 Earnings Beat and Analyst Support</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Adaptive Biotechnologies Soars 8.85% in Pre-market on Strong Q1 Earnings Beat and Analyst Support\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Adaptive Biotechnologies Corp's stock soared 8.85% in pre-market trading on Wednesday, following the company's better-than-expected first-quarter 2026 financial results and positive analyst reactions.</p><p>The significant price increase was driven by the company reporting quarterly revenue of $70.9 million, which exceeded analyst estimates of approximately $61 million and represented a 35% increase year-over-year. Adaptive Biotechnologies also reported a narrower quarterly loss per share of $0.13, beating the consensus estimate of a $0.17-$0.18 loss. The company raised its full-year MRD revenue guidance to $260-$270 million, reflecting accelerating adoption of its clonoSEQ test.</p><p>Further bolstering investor sentiment, multiple analysts maintained positive ratings on the stock, with J.P. Morgan reiterating a Buy rating with a $19.00 price target and Piper Sandler maintaining a Buy rating with a $20.00 price target, highlighting continued confidence in the company's growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADPT","symbol_name":"Adaptive Biotechnologies Corp","start_time":0,"source_url":"","article_id":"1120593580","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120593580","pubTimestamp":1778076326,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Adaptive Biotechnologies Corp's stock soared 8.85% in pre-market trading on Wednesday, following the company's better-than-expected first-quarter 2026 financial results and positive analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADPT":"Adaptive Biotechnologies Corp"},"translate_title":"个股追踪|Adaptive Biotechnologies盘前飙升8.85%，得益于强劲的Q1盈利超出预期和分析师支持","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":1},"content_text":"Adaptive Biotechnologies Corp's stock soared 8.85% in pre-market trading on Wednesday, following the company's better-than-expected first-quarter 2026 financial results and positive analyst reactions.The significant price increase was driven by the company reporting quarterly revenue of $70.9 million, which exceeded analyst estimates of approximately $61 million and represented a 35% increase year-over-year. Adaptive Biotechnologies also reported a narrower quarterly loss per share of $0.13, beating the consensus estimate of a $0.17-$0.18 loss. The company raised its full-year MRD revenue guidance to $260-$270 million, reflecting accelerating adoption of its clonoSEQ test.Further bolstering investor sentiment, multiple analysts maintained positive ratings on the stock, with J.P. Morgan reiterating a Buy rating with a $19.00 price target and Piper Sandler maintaining a Buy rating with a $20.00 price target, highlighting continued confidence in the company's growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120593580","isCrawlerRequest":true}